Bio-Rad Laboratories (BIO) Earns Daily Media Sentiment Rating of 0.22
Media coverage about Bio-Rad Laboratories (NYSE:BIO) has been trending somewhat positive this week, Accern reports. The research firm rates the sentiment of press coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Bio-Rad Laboratories earned a news sentiment score of 0.22 on Accern’s scale. Accern also gave media coverage about the medical research company an impact score of 46.7016874759154 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Here are some of the news headlines that may have effected Accern’s analysis:
- Bio-Rad Laboratories (BIO) Rating Increased to Strong-Buy at Zacks Investment Research (americanbankingnews.com)
- Global Protein Expression Market 2016-2023: Market is Expected to Grow from $1.4 Billion to $3.0 Billion (benzinga.com)
- Global Microfluidics Market Top Key Vendors: Agilent Technologies, Becton, Dickinson And Company, Bio-Rad Laboratories, Inc. (medgadget.com)
- Genetic Analysis and Bio-Rad enter into supply and distribution agreement for GA-map clinical test (news-medical.net)
- Zacks: Brokerages Anticipate Bio-Rad Laboratories, Inc. (BIO) Will Post Quarterly Sales of $617.23 Million (americanbankingnews.com)
A number of research firms recently commented on BIO. Deutsche Bank reiterated a “buy” rating and issued a $255.00 target price on shares of Bio-Rad Laboratories in a research note on Monday, September 18th. Zacks Investment Research upgraded shares of Bio-Rad Laboratories from a “hold” rating to a “strong-buy” rating and set a $291.00 target price for the company in a research note on Wednesday. TheStreet upgraded shares of Bio-Rad Laboratories from a “c+” rating to a “b-” rating in a research note on Monday, November 13th. Finally, Wells Fargo & Company reiterated an “outperform” rating and issued a $290.00 target price (up from $250.00) on shares of Bio-Rad Laboratories in a research note on Wednesday, November 29th. Four investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $277.75.
Bio-Rad Laboratories (NYSE:BIO) traded down $1.64 during mid-day trading on Wednesday, reaching $251.71. 181,734 shares of the company were exchanged, compared to its average volume of 179,508. The firm has a market cap of $7,535.40, a PE ratio of 80.38, a PEG ratio of 3.78 and a beta of 0.97. The company has a quick ratio of 2.77, a current ratio of 4.06 and a debt-to-equity ratio of 0.15. Bio-Rad Laboratories has a one year low of $177.68 and a one year high of $273.87.
Bio-Rad Laboratories (NYSE:BIO) last announced its quarterly earnings data on Thursday, November 2nd. The medical research company reported $0.91 EPS for the quarter, beating the consensus estimate of $0.54 by $0.37. Bio-Rad Laboratories had a net margin of 1.15% and a return on equity of 3.44%. The business had revenue of $535.00 million during the quarter, compared to analysts’ expectations of $507.99 million. During the same period in the previous year, the business posted $0.62 EPS. The business’s quarterly revenue was up 5.2% compared to the same quarter last year. sell-side analysts anticipate that Bio-Rad Laboratories will post 2.68 earnings per share for the current year.
Bio-Rad Laboratories announced that its Board of Directors has approved a stock repurchase plan on Tuesday, November 28th that allows the company to buyback $250.00 million in shares. This buyback authorization allows the medical research company to purchase shares of its stock through open market purchases. Stock buyback plans are generally an indication that the company’s management believes its stock is undervalued.
In other Bio-Rad Laboratories news, EVP Giovanni Magni sold 2,400 shares of Bio-Rad Laboratories stock in a transaction that occurred on Tuesday, November 14th. The shares were sold at an average price of $253.01, for a total transaction of $607,224.00. Following the completion of the sale, the executive vice president now directly owns 9,251 shares in the company, valued at approximately $2,340,595.51. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP James R. Stark sold 746 shares of Bio-Rad Laboratories stock in a transaction that occurred on Thursday, November 30th. The shares were sold at an average price of $270.51, for a total transaction of $201,800.46. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 4,146 shares of company stock valued at $1,067,414. Company insiders own 28.29% of the company’s stock.
WARNING: This article was reported by Watch List News and is owned by of Watch List News. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The original version of this article can be accessed at https://www.watchlistnews.com/bio-rad-laboratories-bio-earns-daily-media-sentiment-rating-of-0-22/1762302.html.
Bio-Rad Laboratories Company Profile
Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.
Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.